June 20 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS NEW PRECLINICAL RESULTS FOR ITS IL-2 SUPERKINE PLATFORM, MDNA109
* MEDICENNA - MDNA109 PROVIDES DURABLE TUMOR CONTROL AND STRONG MEMORY RESPONSE WITHOUT FURTHER TREATMENT WHEN COMBINED WITH CHECKPOINT INHIBITORS